DOP2023000062A - Compuestos y su uso en el tratamiento del cáncer - Google Patents
Compuestos y su uso en el tratamiento del cáncerInfo
- Publication number
- DOP2023000062A DOP2023000062A DO2023000062A DO2023000062A DOP2023000062A DO P2023000062 A DOP2023000062 A DO P2023000062A DO 2023000062 A DO2023000062 A DO 2023000062A DO 2023000062 A DO2023000062 A DO 2023000062A DO P2023000062 A DOP2023000062 A DO P2023000062A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compounds
- treatment
- cancer
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Abstract
La memoria descriptiva se refiere en general a compuestos de Fórmula (I): (I) y sales farmacéuticamente aceptables de estos, en donde A, Z, Y, RA, Conector y v tienen cualquiera de los significados definidos en el presente documento. Esta memoria descriptiva también se refiere al uso de tales compuestos y sales farmacéuticamente aceptables de estos en métodos de tratamiento del cuerpo humano o animal, por ejemplo, en la prevención o el tratamiento del cáncer. Esta memoria descriptiva también se refiere a procesos y compuestos intermedios involucrados en la preparación de tales compuestos y a composiciones farmacéuticas que los contienen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063085384P | 2020-09-30 | 2020-09-30 | |
PCT/EP2021/076752 WO2022069520A1 (en) | 2020-09-30 | 2021-09-29 | Compounds and their use in treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2023000062A true DOP2023000062A (es) | 2023-05-31 |
Family
ID=78085628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2023000062A DOP2023000062A (es) | 2020-09-30 | 2023-03-24 | Compuestos y su uso en el tratamiento del cáncer |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230374007A1 (es) |
EP (1) | EP4221756A1 (es) |
JP (1) | JP2023543299A (es) |
KR (1) | KR20230079408A (es) |
CN (1) | CN116249554A (es) |
AU (1) | AU2021353968A1 (es) |
BR (1) | BR112023005708A2 (es) |
CA (1) | CA3195695A1 (es) |
CL (1) | CL2023000881A1 (es) |
CO (1) | CO2023005188A2 (es) |
CR (1) | CR20230185A (es) |
DO (1) | DOP2023000062A (es) |
EC (1) | ECSP23030959A (es) |
IL (1) | IL301626A (es) |
MX (1) | MX2023003564A (es) |
PE (1) | PE20230782A1 (es) |
WO (1) | WO2022069520A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115141179A (zh) * | 2021-03-31 | 2022-10-04 | 江苏恒瑞医药股份有限公司 | 一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用 |
WO2023180388A1 (en) | 2022-03-24 | 2023-09-28 | Glaxosmithkline Intellectual Property Development Limited | 2,4-dioxotetrahydropyrimidinyl derivatives as degrons in protacs |
USD1018747S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
USD1018746S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
USD1018676S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
USD1020957S1 (en) * | 2022-04-15 | 2024-04-02 | Puttshack LTD | Miniature golf hole |
WO2024056005A1 (zh) * | 2022-09-14 | 2024-03-21 | 先声再明医药有限公司 | 多并环类化合物及其用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0422263D0 (en) | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
DK2558446T5 (da) | 2010-04-16 | 2019-12-09 | Ac Immune Sa | Nye forbindelser til behandling af sygdomme associerede med amyloid- eller amyloidlignende proteiner |
MX355943B (es) | 2013-06-26 | 2018-05-07 | Abbvie Inc | Carboxamidas primarias como inhibidores de btk. |
AR102094A1 (es) | 2014-09-25 | 2017-02-01 | Araxes Pharma Llc | Inhibidores de proteínas kras con una mutación g12c |
MX2019009046A (es) | 2017-01-31 | 2019-10-30 | Arvinas Operations Inc | Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo. |
EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND THEIR USES |
-
2021
- 2021-09-29 US US18/247,014 patent/US20230374007A1/en active Pending
- 2021-09-29 CA CA3195695A patent/CA3195695A1/en active Pending
- 2021-09-29 KR KR1020237014514A patent/KR20230079408A/ko unknown
- 2021-09-29 PE PE2023001220A patent/PE20230782A1/es unknown
- 2021-09-29 WO PCT/EP2021/076752 patent/WO2022069520A1/en active Application Filing
- 2021-09-29 BR BR112023005708A patent/BR112023005708A2/pt unknown
- 2021-09-29 EP EP21787317.3A patent/EP4221756A1/en active Pending
- 2021-09-29 CN CN202180065971.2A patent/CN116249554A/zh active Pending
- 2021-09-29 JP JP2023519522A patent/JP2023543299A/ja active Pending
- 2021-09-29 AU AU2021353968A patent/AU2021353968A1/en active Pending
- 2021-09-29 CR CR20230185A patent/CR20230185A/es unknown
- 2021-09-29 IL IL301626A patent/IL301626A/en unknown
- 2021-09-29 MX MX2023003564A patent/MX2023003564A/es unknown
-
2023
- 2023-03-24 DO DO2023000062A patent/DOP2023000062A/es unknown
- 2023-03-27 CL CL2023000881A patent/CL2023000881A1/es unknown
- 2023-04-24 CO CONC2023/0005188A patent/CO2023005188A2/es unknown
- 2023-04-27 EC ECSENADI202330959A patent/ECSP23030959A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023543299A (ja) | 2023-10-13 |
CN116249554A (zh) | 2023-06-09 |
CL2023000881A1 (es) | 2023-11-17 |
AU2021353968A1 (en) | 2023-06-08 |
ECSP23030959A (es) | 2023-05-31 |
MX2023003564A (es) | 2023-04-04 |
CO2023005188A2 (es) | 2023-05-19 |
US20230374007A1 (en) | 2023-11-23 |
PE20230782A1 (es) | 2023-05-09 |
CA3195695A1 (en) | 2022-04-07 |
WO2022069520A1 (en) | 2022-04-07 |
IL301626A (en) | 2023-05-01 |
CR20230185A (es) | 2023-06-27 |
KR20230079408A (ko) | 2023-06-07 |
EP4221756A1 (en) | 2023-08-09 |
BR112023005708A2 (pt) | 2023-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023005188A2 (es) | Compuestos y su uso en el tratamiento del cáncer | |
UY38625A (es) | Compuestos y su uso en el tratamiento del cáncer | |
ECSP21080740A (es) | Inhibidores del inflamasoma nlrp3 | |
CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
CL2022003289A1 (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer | |
NI202000099A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
CO2018004933A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
CR20110270A (es) | Piriloxi-indoles Inhibidores del VEGF-R2 y Uso de los Mismos para el Tratamiento de Enfermedades | |
CO2022014073A2 (es) | Compuestos antivirales y métodos para la administración de los mismos | |
UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
CO6300957A2 (es) | Derivados de imidazo -[1,2,b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met | |
CL2004000590A1 (es) | Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v | |
NI201900094A (es) | COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
ECSP19084722A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
CO2017011969A2 (es) | Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios | |
AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
BR112019000813A2 (pt) | formas sólidas de inibidor de ttk | |
CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") |